GCC Pharmaceutical Market Sales Size Report 2025
According to “GCC Pharmaceutical Market Opportunity Insight 2025” Report, the pharmaceutical market opportunity in GCC is expected to surpass US$ 20 Billion by 2025. The GCC pharma market has been witnessing exponential growth driven by high demand of branded and patented drugs.
“GCC Pharmaceutical Market Opportunity Insight 2025” Report Highlights:
- GCC Pharmaceutical Market Opportunity: > US$ 20 Billion
- Patented & OTC Pharmaceutical Market Size: 75% of Total Market
- Share of Imported Drugs In GCC Pharmaceutical Market: > 80%
- Saudi Arabia Dominates GCC Pharmaceutical Market: 50% Market Share
- GCC Pharmaceutical Clinical Trials Insight: > 700 Drugs
Download Report: https://www.kuickresearch.com/report-gcc-pharmaceutical-market-opportunity-insight-2025.php
Table of Contents
- Introduction to Gulf Cooperation Council (GCC) Pharmaceutical Market
1.1 Overview
1.2 GCC Pharmaceutical Market Analysis
- GCC Pharmaceutical Market by Indication – Prevalence & Statistics
2.1 Cancer
2.1.1 Overview
2.1.2 Prevalence by Cancer Type & Gender
2.1.3 Cancer Prevalence & Statistics by GCC Countries
2.2 Diabetes
2.3 HIV/AIDS
2.4 Cardiovascular Diseases
2.4.1 Coronary Heart Disease
2.4.2 Hypertension
2.4.3 Stroke
2.5 Obesity
2.6 Respiratory Disorders
2.6.1 Asthma
2.6.2 Tuberculosis
2.6.3 Influenza & Pneumonia
2.6.4 Other Respiratory Diseases – COPD & Cystic Fibrosis
2.7 Alzheimer’s Disease/Dementia
- GCC – Regulatory Aspects of Pharmaceuticals
3.1 Gulf Central Committee for Drug Registrations (GCC-DR)
3.2 Regulatory Review Process
3.3 Centralized Registration
3.4 Decentralized Drug Registration Regulation
3.4.1 Saudi Arabia
3.4.2 Kuwait
3.4.3 UAE
3.4.4 Bahrain
3.4.5 Qatar
3.4.6 Oman
3.5 Gulf Joint Procurement Program
- GCC – Pharmaceutical Pricing & Reimbursement Policies
4.1 Pricing Policies
4.1.1 In-Patent Pharmaceuticals
4.1.2 Off-Patent & Generic Pharmaceuticals
4.1.3 Locally & Multinational Manufactured Pharmaceuticals
4.2 Procurement & Reimbursement Policies
4.2.1 In-Patent Pharmaceuticals
4.2.2 Off-Patent, Generics & Biosimilars
- GCC Pharmaceutical Market by Product
5.1Generics Pharmaceuticals
5.2 Patented & OTC Pharmaceuticals
5.3 Biosimilars
- Saudi Arabia Pharmaceutical Market Analysis
6.1 Overview
6.2 Saudi Arabia Pharmaceutical Market by Products
6.3 Saudi Arabia Pharmaceutical Market by Companies
6.4 Saudi Arabia Pharmaceutical Market by Type
- UAE Pharmaceutical Market Analysis
7.1 Overview
7.2 UAE Pharmaceuticals Market by Product
7.3 UAE Pharmaceutical Market by Companies
7.4 UAE Pharmaceutical Market by Type
- Kuwait Pharmaceutical Market Analysis
8.1 Overview
8.2 Kuwait Pharmaceutical Market by Therapeutic Indication & Products
8.3 Kuwait Pharmaceutical Market by Companies
8.4 Kuwait Pharmaceutical Market by Type
- Bahrain Pharmaceutical Market Analysis
9.1 Overview
9.2 Bahrain Pharmaceutical Market by Products
9.3 Bahrain Pharmaceutical market by Companies
9.4 Bahrain Pharmaceutical Market by Product Type
- Qatar Pharmaceutical Market Analysis
10.1 Overview
10.2 Qatar Pharmaceutical Market by Type
- Oman Pharmaceutical Market Analysis
11.1 Overview
11.2 Oman Pharmaceutical Market by Product Type
- GCC Pharmaceutical Market – International Trade
12.1 Import Market
12.2 Pharmaceutical Export Market
- GCC Pharmaceutical Market – Clinical Trials Insight
13.1 Overview
13.2 Clinical Trials by Indication
13.2.1 Cancer
13.2.2 Diabetes
13.2.3 CVS Disorders
13.2.4 Respiratory Disorders
13.3 Clinical Insight by GCC Countries
13.3.1 Saudi Arabia
13.3.2 United Arab Emirates
13.3.3 Kuwait
13.3.4 Bahrain
13.3.5 Qatar
13.3.6 Oman
- GCC Pharmaceutical Market Drivers
- Challenges for GCC Pharmaceutical Market
- GCC Pharmaceutical Market Future Outlook – Trends & Opportunities
- Competitive Landscape
17.1 Local Pharmaceutical Companies
17.1.1 Julphur Pharmaceuticals
17.1.2 SPIMACO Addwaeih
17.1.3 Qatar Life Pharma
17.1.4 Al Mojil Drug Company
17.1.5 Kuwait Saudi Pharmaceutical Company
17.1.6 YIACO Medical Company
17.1.7 Qatar Pharma
17.1.8 Saja Pharmaceuticals
17.1.9 Oman Pharmaceuticals
17.1.10 Taiba Pharmaceuticals
17.1.11 Gulf Biotech
17.1.12 Bahrain Pharma
17.1.13 Neopharma
17.1.14 Planet Pharmacies
17.1.15 Aljazeera Pharmaceutical Industries
17.1.16 Dallah Pharma
17.1.17 Tabuk Pharmaceuticals
17.1.18 CAD Middle-East Pharmaceutical Company
17.1.19 ACDIMA
17.1.20 AL-Mufid Pharmaceuticals
17.2 Multinational Companies
17.2.1 Novartis
17.2.2 Amgen
17.2.3 Eli – Lilly
17.2.4 Merck
17.2.5 Pfizer
17.2.6 GlaxoSmithKline plc
17.2.7 Roche
17.2.8 Takeda Pharmaceuticals
17.2.9 Teva Pharmaceuticals
17.2.10 AstraZeneca plc
17.2.11 Genentech
17.2.12 Sanofi
Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-11-47067990